

CURRICULUM VITAE

January 14, 2010

ANIRBAN BASU

Section of Hospital Medicine, Department of Medicine, University of Chicago
5841 S. Maryland Ave., MC-2007, AMD B226C, Chicago IL 60637
Email: abasu@medicine.bsd.uchicago.edu Web: <http://home.uchicago.edu/~abasu>
Tel: +1 773 834 1796 Fax: +1 773 834 2238

EDUCATION

B.S. Pharmaceutical Technology, Jadavpur University, India, July 1995.
M.S. Pharmaceutical Sciences, University of Toledo, August 1997.
M.S. Biostatistics, University of North Carolina, Chapel Hill, May 1999.
Ph.D. Public Policy (Health Economics), University of Chicago, June 2004.
Dissertation: *Three essays in medical cost-effectiveness analysis.*

PROFESSIONAL EXPERIENCE

Jun '97 – Aug '97 RESEARCH ASSOCIATE, Statistics Collaborative Inc., Washington DC.
Aug '97 – May '99 RESEARCH ASSISTANT, Collaborative Studies Coordinating Center, UNC-CH.
May '99 – Aug '99 CONSULTANT, Dept. of Statistics, Abbott Laboratories Inc., Abbott Park, IL.
Apr '00 – Sep '00 RESEARCH ASSISTANT, National Opinion Research Center, University of Chicago, IL.
Jul '04 – Jun '06 INSTRUCTOR, Section of General Internal Medicine, Department of Medicine,
University of Chicago, IL.
Oct '04 – Jun '06 PROJECT ANALYST, Decision and Information Sciences, Argonne National Laboratory, IL.
Jul '05 – Present AFFILIATE, Center for Health and the Social Sciences, University of Chicago, Chicago, IL.
Feb '06 – Present MEMBER, Clinical Cancer Genetics and Prevention Program at the University of Chicago Cancer
Center, Chicago, IL.
Jul '06 – Present ASSISTANT PROFESSOR, Department of Medicine, University of Chicago, IL.
Jul '06 – Jun '08 Section of General Internal Medicine
Jul '08 – Present Section of Hospital Medicine
Jul '07 – Present EXTERNAL AFFILIATE, Health Econometrics and Data Group, The University of York, UK.
May'08 – Present FACULTY RESEARCH FELLOW, National Bureau of Economic Research, Cambridge, MA.

AWARDS & HONORS

1993 Diploma in Computer Programming and Applications from National Computing Center, UK with
DISTINCTION award
1995 First Class Honors in Bachelors Degree in Pharmaceutical Sciences
1996 Outstanding Academic Performance, Rho Chi Society, University of Toledo, Ohio
1999 – 2004 Irving Harris Fellowship Award from the School of Public Policy, University of Chicago
2003 Winner of Student Paper competition, Health Policy Statistics Section for the 2003 Joint Statistical
Meetings
2003 Winner of Student Travel Award, International Conference Health Policy Research, 2003
2005 Wodecroft Young Investigator Award, National Alliance for Research of Schizophrenia and
Depression (NARSAD)
2007 Research Excellence Award for Methodological Excellence, International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
2008 Recipient of Alan Williams Health Economics Fellowship, University of York, UK.
2009 ISPOR Bernie O'Brien New Investigator Award, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR)
2009 2009 Labelle Lecturer in Health Services Research, McMaster University, Canada
2009 Society for Medical Decision Making Comparative Effectiveness Research Essay Contest Winner.
2010 Inducted to Marquis Who's Who in America

TEACHING EXPERIENCE

- Sept '95 - May '97 TEACHING ASSISTANT, College of Pharmacy, University of Toledo, Toledo, OH.
- Aug '98 - Dec '98 TEACHING ASSISTANT, Department of Biostatistics, University of North Carolina at Chapel Hill.
- Oct '00 - Dec '03 TEACHING ASSISTANT, Harris School of Public Policy Studies, University of Chicago.
- Jan '00 - June '04 GRADUATE ASSISTANT, University of Chicago
- Jul '04 - Present STATISTICAL CONSULTANT AND MENTOR to many faculties, research scholars and medical students in the Department of Medicine. (4 hours/week)
- Mar '07 - Present LECTURER:
Advanced Applications of Cost-Effectiveness Analysis in Health (Public Policy 44800)
Spring 2007 (with David Meltzer). Teach five 2.5 hour sessions.
- Applied Medical Cost-Effectiveness Analysis (Public Policy 46000)*
Winter 2008, 2009 (with William Dale, Elbert Huang, David Meltzer & Harold Pollack).
Teach two 2.5 hour sessions.
- Advanced Methods for Comparative Effectiveness Research (Public Policy 44800)*
Spring 2010 (with David Meltzer). Teach five 2.5 hour sessions.

ADVISING

- 2003 – 2009: Thesis Committee Member, Jennifer Humensky, Ph.D. (Presently: Post-Doc, Veterans Affairs, Hines, IL)
- 2006 – Present: Mentor, Lisa Shah M.D., Hospital Scholar, University of Chicago.
- 2009 – Present: Thesis Committee Member, Anjali Oza, Student, Public Policy, University of Chicago
- 2008 Advisory Board Member for Amgen Inc. on Alternative Estimators for Unbiased Treatment Effects, July 2008.
- 2009 Advisory Board Member for Ortho-McNeil Janssen Scientific Affairs LLC. for People with Mental Illness in the Criminal Justice System, August 2009.

EDITORIAL ACTIVITIES

- Jan '09 – Present ASSOCIATE EDITOR, Health Economics (*Handle up to 15 papers a year*)
- Nov '08 – Present ASSOCIATE EDITOR, Journal of Health Economics (*Handle up to 5 papers a year*)
- Jun '03 – Present REVIEWER for
Applied Economics: Journal of Health Economics, Health Economics, Journal of Mental Health Policy and Economics, PharmacoEconomics
Statistics: Statistics in Medicine, Journal of the Royal Statistical Society- Series B, Health Services and Outcomes Research Methodology, Operations Research
Health Services Research: Medical Decision Making, Value in Health, Pharmacoepidemiology and Drug Safety, *Health Services Research*
Clinical: Stroke, Journal of Clinical Psychopharmacology, Stroke, Journal of the National Cancer Institute
Grants: National Science Foundation, Research Grants Council (RGC) of Hong Kong, National Institute of Health (NIH)

PROFESSIONAL AFFILIATIONS

- International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
- American Statistical Association (ASA)
- International Health Economics Association (iHEA)
- American Society of Health Economists (ASHE)
- Society for Medical Decision Making (SMDM)

PROFESSIONAL SERVICE

Health Policy Statistics Section, American Statistical Association

- 2005 Member, International Conference for Health Policy Research (ICHPR) Scientific Planning Committee, Boston, MA.
- 2007 Program Chair-Elect.
- 2008 Program Chair.
- 2008 Member, International Conference for Health Policy Statistics (ICHPS), Scientific Planning Committee, Philadelphia, PA.
- 2010 Conference Co-Chair, International Conference for Health Policy Statistics (ICHPS), Washington DC.

Society for Medical Decision Making

- 2008 Member, Nominations Committee.
- 2009 Co-Chair, Scientific Committee for Annual Meeting
- 2010 Co-Chair, Scientific Committee for Annual Meeting
- 2011 Annual Conference Co-Chair, Chicago IL.

Others

- 2005-2007 Member, American Society of Health Economist (ASHE) Scientific Committee.
- 2008 Committee Member, Behavioral Health Theme, Annual Research Meeting, Academy Health.
- 2008 Program Committee Member, The 14th NIMH Biennial Research Conference on the Economics of Mental Health: Toward Building a High Performance Mental Health System
- 2008- Member of Technical Panel for Johns Hopkins University Evidence-Based Practice Center Project: *Evaluating Economic Outcomes in Systematic Reviews*
- 2009 - Founding Member of the Annual Health Econometrics Conference and the Chair of Inaugural Conference, Chicago, 2009 (www.healtheconometrics.org)
- 2010 Committee Member, Comparative Effectiveness Research Theme, Annual Research Meeting, Academy Health.
- 2010 Chair, AHRQ Comparative Effectiveness Research Special Interest Group

CURRENT RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
A comprehensive probabilistic microsimulation model for cost-effectiveness analysis of pharmacological treatment algorithms in schizophrenia	Principal Investigator	R01; NIMH (NIH) 1R01 MH083706-01	9/01/08 – 8/30/13	\$1,970,439 (6.0 CYE)
Hospital Medicine and Economics	Co-Investigator (Economics Core) PI: Meltzer (UofC)	U18 (AHRQ) Center for Evaluation and Research in Therapeutics (CERT)	09/01/2007 – 3/31/2011	- (1.2 CYE)
Immunotherapy Innovations in Cancer: Cost, Access Barrier, and Pattern of Care	Co-Investigator PI: Dr. Tina Shih (UT-MD Anderson)	National Cancer Institute (NIH)	9/1/2009- 8/31/2013	\$72,429 (1.80 CYE)

PENDING RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
Comparative Effectiveness of Dynamic Patterns of Glucose Lowering Therapies	Co-Investigator PI: Dr. Elbert Huang (UofC)	Agency for Health Care Research and Quality (AHRQ)	12/1/2009-11/30/2014	\$1,626,108 (2.40 CYE)
Towards a Transformational Change in Comparative Effectiveness Research	Principal Investigator	2010 NIH Director's Pioneer Award Program (DP1)	7/1/2010-6/30/2015	\$2,500,000 (6.00 CYE)

PAST RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
Causal Estimation of the Intention-To-Treat Treatment Effect in Randomized Trials	Principal Investigator	Center for Health Administration Studies (CHAS) Seed Grant	07/01/05 – 06/30/06	\$7,500
Measuring spillover effects of prostate cancer patients' health on their partners	Principal Investigator	UofC, Cancer Research Center, Cancer and Social Sciences Pilot Project	03/01/05 - 6/30/07	\$20,000
Model for cost-effectiveness analysis of the REACH-OUT Chicago Children's Diabetes Prevention Project	Principal Investigator	The Chicago Center of Excellence in Health promotion Economics, Pilot Grant Award	03/01/05 - 02/28/06	\$18,608
Estimating risks and costs of cardiovascular diseases associated with the long-term use of atypical antipsychotics in schizophrenia	Principal Investigator	NARSAD Young Investigator Award	07/01/05 – 06/30/08	\$60,000
Measuring the effects of patient's health on family members' quality of life and incorporating them in cost-effectiveness analysis	Principal Investigator	Pfizer Cost-effectiveness Grant	01/01/06 – 12/31/07	\$60,000
Quality-of-life and willingness-to-pay for clinical symptoms and social outcomes of patients with schizophrenia	Principal Investigator	University of Chicago CCEHPE Pilot Grant	07/01/07 – 06/30/08	\$22,000
REACH-OUT Chicago Children's Diabetes Prevention Project	Co-Investigator PI: Deborah Burnet (UofC)	R01, NIDDK(NIH) 1 R18 DK62991-01A2	9/30/04 - 6/30/09	\$2,049,866 (3.75 CYE)
Artificial Pancreas Project Health Economics Follow-On Study	Co-Investigator PI: Michael O'Grady (NORC)	Juvenile Diabetes Research Foundation 22-2006-1126	9/01/06 – 8/31/09	\$459,388 (2.40 CYE)

INVITED LECTURES AND PROFESSIONAL PRESENTATIONS

Topics:

Welfare consequences of comparative effectiveness research.

Tragedy of averages in comparative effectiveness research: The case for antipsychotics and diabetes.

Comparative effectiveness research in prostate cancer: building the blocks.

Antipsychotics and diabetes in schizophrenia: Did comparative effectiveness research make a difference?

Antipsychotics-induced economic burden of diabetes in schizophrenia.

Economic incentives to invest in comparative effectiveness research using Bayesian adaptive trials.

The impact of the Medicare Part D prescription benefit on drug utilization and expenditures: the case for dual-eligibles.

Use of propensity scores in non-linear response models.

A time trade-off method to elicit preferences of spouses about the influence of their husbands' potential prostate cancer health states on them.

Understanding assumptions behind propensity scores versus instrumental variable estimators: how do we interpret estimates of incremental costs?

Risk prediction index for new onset major depression in the national longitudinal study of adolescent health.

A simple linear function to predict joint state utilities from single state utilities in prostate cancer.

Use of instrumental variables in the presence of heterogeneity and self-selection: An application in breast cancer patients.

Spillover effects of health on family members: Theoretical and measurement issues.

Risk adjustment with flexible link and variance function models.

Impact of heart failure on 1-year costs after myocardial infarction related hospitalization: an application using a flexible link and variance function model.

Comparing alternative models: log vs Cox proportional hazard.

Estimating marginal and incremental effects on health outcomes using flexible link and variance function parameters.

Family perspective in economic evaluation of medical technology (Alternative title Friends, families and cost-effectiveness analysis).

Modeling costs with generalized gamma regressions.

Hierarchical Linear Models.

Venues: Intramural

Demography Workshop, October 2002.

Health Studies Seminar Series, April 2003, January 2008, November 2008.

Center for Health Administration (CHAS) Workshop, November 2003.

Health Economics Workshop, June 2001, October 2003, March 2005, June 2006.

Research in Progress, General Internal Medicine, March 2004, March 2006.

Venues: National

Invited Speaker, American Public Health Association Annual Meeting, Philadelphia, November, 2002.

International Biometric Society (ENAR) Spring Meeting, Tampa, April 2003.

International Health Economics Association (iHEA) Bi-annual Congress, San Francisco, June 2003.

Tools and Methods for Designing, Performing, and Reporting Primary Care Research Based Practice Networks Research.
Sponsored session by The Agency for Healthcare Research and Quality, Washington DC, July, 2003.

Joint Statistical Meeting, Health Policy Statistics Section, San Francisco, August 2003.

Society for Medical Decision Making (SMDM) Annual Meeting, Chicago, October 2003.

International Conference on Health Policy Research, Chicago, October 2003.

Department of Health Policy and Administration, Yale University, May 2004.

Keynote Speaker, Third Annual Advanced Research Methods Symposium, Center for Disease Control, May 2004.

Society for Medical Decision Making, Annual Meeting, October 2004.
Department of Health Care Policy, Harvard Medical School, January 2005.
Invited Speaker, International Conference on Health Policy Research (iHEA) Bi-annual Meeting. Boston, October, 2005.
Center for Pharmacoeconomics Research, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, August, 2005.
American Society for Health Economists (ASHE) Inaugural Meeting. Madison WI, June, 2006.
Health Economics Brown Bag Seminar Series, Department of Economics, University of Illinois at Chicago, Chicago. September, 2006
Society for Medical Decision Making, Annual Meeting, October 2006.
Academy Health, Annual Research Meeting, June 2007.
Society for Medical Decision Making, Annual Meeting, October 2007.
Invited Speaker, International Conference for Health Policy Statistics (ICHPS), Philadelphia, January 2008.
Center for Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, Northwestern University, March 2008.
2nd Biennial Conference of the American Society of Health Economists. Duke NC, June 2008.
Amgen Alternative Estimators for Unbiased Treatment Effects Advisory Board, July 2008.
Invited Speaker, Society for Medical Decision Making, Annual Meeting, October 2008.
Invited Speaker, Society for Judgment and Decision Making, Annual Meeting, November 2008.
Invited Speaker, International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting, May 2009.
20th NIMH Conference on Mental Health Services Research (MHSR), Washington DC, July, 2009.
Invited Speaker, Grand Rounds, Department of Psychiatry, Vanderbilt University, June, 2009.
Invited Speaker, Specialized Programs of Research Excellence (SPORE) in prostate cancer, Northwestern University, September 2009.
The 31st Annual Meeting of the Society for Medical Decision Making, Hollywood CA, October, 2009.
20th Annual Health Economics Conference, Boston MA, October 2009.
Invited Speaker, Rice/University of Houston Empirical Seminar Series, October, 2009.

Venues: International

International Health Economics Association (iHEA) Bi-annual Congress. Organized session on Health Econometrics for Cost and Utilization Data. Barcelona, July, 2005.
International Health Economics Association (iHEA) Bi-annual Congress. Copenhagen, July 2007.
CHE-TEEHTA Seminar, University of York, York UK, May 2008.
Section of Public Health and Health Policy, University of Glasgow, UK, May 2008.
HEDG Group, University of York, York, UK, May 2008.
17th European Workshop of Econometrics and Health Economics, Coimbra, Portugal, September 2008.
18th European Workshop of Econometrics and Health Economics, Cagliari, Italy, September 2009.
Invited Speaker, 2009 Labelle Lecture, McMaster University, Canada, October, 2009.

Discussant for:

Use of Bayesian Net Benefit regression to update cost-effectiveness analysis. The 13th NIMH Biennial Research Conference on the Economics of Mental Health. Washington DC, September 2006.
Budget constraints in expected utility analysis. 2nd Biennial Conference of the American Society of Health Economists. Duke NC, June 2008.

PUBLICATIONS (original peer-reviewed articles)

1. **Basu A**, Tong P, Alexander KS, Dollimore D. Extension of the compartment theory for hindered settling behavior." *S.T.P. Pharma Sciences* 1997; 7(3): 215-222.
2. Tong P, **Basu A**, Alexander KS, Dollimore D. Development of a new theory for hindered settling suspensions. *S.T.P. Pharma Sciences* 1998; 8(4): 241-247.
3. Abdalla I, **Basu A**, Hellman S. An evidence-based analysis of the management of localized prostate cancer. *The Cancer Journal* 2002. Jan-Feb; 8(1): 40-6. [PMID: 11895202]
4. Meltzer D, Chung J, **Basu A**. Does competition under Medicare prospective payment selectively reduce expenditures on high-cost patients? *RAND Journal of Economics* 2003; 33(3): 447-468. [PMID: 12585302]
5. Jani AB, **Basu A**, Heinmann R, Hellman, S. Sentinel node versus axillary node dissection for the early stage breast cancer: A comparison using a utility-adjusted NNT (Number Needed to Treat) analysis. *Cancer* 2003; January; 97(2): 359-366. [PMID: 12518360]
6. Jani AB, **Basu A**, Abdalla I, Connell PP, Krautz L, Vijayakumar S. The impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate or high-risk prostate cancer. *American Journal of Clinical Oncology* 2003; August 26(4):382-385. [PMID: 12902891]
7. **Basu A**, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? *Health Economics* 2004; 13(8): 749-765. [PMID: 15322988]
8. **Basu A**. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. *Schizophrenia Research* 2004; 71(2-3): 445-462. [PMID: 15474916]
9. **Basu A**, Rathouz P. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. *Biostatistics* 2005; 6(1): 93-109. [PMID: 15618530]
10. Manning WG, **Basu A**, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes. *2003 NBER Working Paper* No. t0293. *Journal of Health Economics* 2005; 24(3): 465-488. [PMID: 15811539]
11. Dickinson M, **Basu A**. Multilevel modeling and practice-based research. *Annals of Family Medicine* 2005; 3(Supp 1): S52-S60.
12. **Basu A**, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. *Journal of Health Economics* 2005; 24(4): 751-773. [PMID: 15960995]
13. **Basu A** Extended generalized linear models: Simultaneous estimation of link and variance functions. *The Stata Journal* 2005; 5(4): 501-516.
14. Lindau ST, **Basu A**, Leitsch SA. Health literacy as a predictor of follow-up after an abnormal pap smear: A prospective study. *Journal of General Internal Medicine* 2006; 21(8): 829 – 834. [PMID: 16881942]
15. **Basu A**, Meltzer HY, Dukic V. Estimating transitions between symptom severity states over time in schizophrenia: A Bayesian meta-analytic approach. *Statistics in Medicine* 2006; 25(17): 2886 - 2910. [PMID: 16220519]
16. **Basu A**, Arondekar BV, Rathouz P. Scale of interest versus scale of estimation: Comparing alternative estimators for the incremental costs of a comorbidity. *Health Economics* 2006; 15(10): 1091-1107. [PMID: 16518793]
17. **Basu A**, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. *Schizophrenia Research* 2006; 86(1-3): 99-109. [PMID: 16753284]
18. **Basu A**, Manning WG. A test for proportional hazards assumption within the class of exponential conditional mean framework. *Health Services and Outcomes Research Methodology* 2006; 6(3-4): 81-100.
19. **Basu A**, Meltzer D. Value of information on preference heterogeneity and individualized care. *Medical Decision Making* 2007; 27(2):112-127. [PMID: 17409362]
20. Huang ES, **Basu A**, Finch M, Frytak J, Manning WG. The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. *Current Medical Research and Opinion* 2007; 23(6): 1423-1430. [PMID: 17559738]
21. **Basu A**, Heckman J, Navarro-Lozano S, Urzua S. Use of instrumental variables in the presence of heterogeneity and self-selection: An application to treatments of breast cancer patients. York Health Econometrics and Data Group (HEDG) Working Paper 07/07. (with Editorial) *Health Economics* 2007; 16(11): 1133 -1157. [PMID: 17910109]
22. Yin W, **Basu A**, Zhang J, Rabbani A, Meltzer DO, Alexander GC. The impact of the Medicare Part D prescription drug benefit on drug utilization and out-of-pocket expenditures. (with Editorial) *Annals of Internal Medicine* 2008; 148: 169-177. [PMID: 18180465]
23. Dale W, **Basu A**, Meltzer D, Elstein A. Predicting utility ratings for joint health states from single health states in prostate cancer: Empirical testing of alternative theories. *Medical Decision Making* 2008; 28(1): 102 – 112. [PMID: 18057188]
24. Alexander GC, Zhang J, **Basu A**. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. *Medical Care* 2008; 46: 394-402.[PMID: 18362819]
25. Terza JV, **Basu A**, Rathouz PJ. Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. *Journal of Health Economics* 2008; 27(3):531-543. [PMID: 18192044]

26. **Basu A**, Paltiel DA, Pollack HA. Social costs of robbery and the cost-effectiveness of substance abuse treatment. *Health Economics* 2008; 17(8): 926-948. [PMID: 17992708]
27. Van Voorhees BW, Paunesku D, Kuwabara SA, **Basu A**, Gollan J, Hankin BL, Melkonian S, Reinecke M. Protective and vulnerability factors predicting new-onset depressive episode in a representative of US adolescents *Journal of Adolescent Health* 2008;42(6):605-16.[PMID: 18486870]
28. Van Voorhees BW, Ellis JM, Gollan J, **Basu A**. Predicting future risk of depressive episode in adolescents: the Chicago Adolescent Depression Risk Assessment (CADRA). *Annals of Family Medicine* 2008 Nov-Dec;6(6):503-511 [PMID: 19001302]
29. **Basu A**, Dale W, Elstein A, Meltzer D. A Linear Index for Predicting Joint Health States Utilities from Single Health States Utilities. *Health Economics* 2009; 18(4): 403-419. [PMID: 18773392]
30. **Basu A**, Manning WG. Issues for the next generation of healthcare costs analyses. *Medical Care* 2009; 47(7_Supplement_1):S109-S114. [PMID: 19536022]
31. Meltzer D, **Basu A**, Meltzer HY. Comparative Effectiveness Research for Antipsychotic Medications: How Much Research is Enough? *Health Affairs* 2009; 28(5): w794-w808 [PMID: 19622539]
32. Huang E, **Basu A**, O'Grady M, Capretta JC. Using Clinical Information To Project Federal Health Care Spending. *Health Affairs* 2009; 28(5):w978-w990 [PMID: 19723699]
33. Huang E, **Basu A**, O'Grady M, Capretta J. Projecting the Future Diabetes Population Size and Related Costs for the United States. *Diabetes Care* 2009; 32:2225-2229. [PMID: 19940225]
34. **Basu A**. Individualization at the Heart of Comparative Effectiveness Research: The Time for *i*-CER has Come. *Medical Decision Making*. 2009. 29(6): N9-N11. [PMID: 19959807] [<http://mdm.sagepub.com/cgi/reprint/29/6/NP9>]
35. **Basu A**, Yin W, Alexander CG. Impact of Medicare Part D on the prescription utilization of elderly dual-eligible patients. *2008 NBER Working Paper* No. w14413. *Health Services Research*. 2009. 45(1): 133-151. [PMID: 20002765]
36. Shah LM, King AC, **Basu A**, Krishnan JA, Borden WB, Meltzer D, Arora V. The Preparedness of Hospitalized Patients to Quit Smoking. *Journal of Hospital Medicine*. 2009. In Press.
37. **Basu A**, Dale William, Elstein A, Meltzer D. A Time-Trade-off Method for Eliciting Partner's Quality of Life due to Patient's Health States in Prostate Cancer. *Medical Decision Making*. In press.
38. **Basu A**. Forecasting distribution of body-mass index categories in United States: Is there more room for growth? *Medical Decision Making*. In press.

PUBLICATIONS (book chapters)

1. Polsky D, **Basu A**. Selection bias in observational data. In *Elgar Companion to Health Economics*. Ed. Jones A., Chap 43: 455 - 465, Edward Elgar Publishing Inc., UK, 2006.
2. **Basu A**, Lehman A. Decision Analytic Techniques. In *Difficult Decisions in Thoracic Surgery - An Evidence-Based Approach*. Ed. Ferguson M., Springer, NY, 2007.
3. Meltzer D, **Basu A**, and Conti R. The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives. Draft manuscript prepared at the request of the IOM Roundtable on Evidence-Based Medicine, University of Chicago, 2007.

PUBLICATIONS (letters, editorials)

1. **Basu A**. Cost-effectiveness of olanzapine as a first-line treatment: A comment. *Value in Health (Letter)* 2006; 9(5): 357. [PMID: 16961554]
2. **Basu A**, Meltzer D. Modeling Comparative Effectiveness and the Value of Research. *Annals of Internal Medicine (Editorial)* 2009; 151: 210-211. [PMID: 19652188]

BOOK REVIEWS

- Basu A**. Review of *Bayesian Econometric Methods* by Koop, Poirier and Tobias. *Journal of the American Statistical Association* 2009; 104(487): 1273.

PUBLICATIONS (under review)

1. **Basu A**, Philipson T. Impact of comparative effectiveness research on health and healthcare spending. 2010 *NBER Working Paper* No. w15633.
2. **Basu A**. Economics of individualization in comparative effectiveness research.

3. **Basu A**, Polsky D, Manning WG. Do propensity score methods suffer from the curse of dimensionality? Finite sample evidence from non-linear response models. York Health Econometrics and Data Group (HEDG) Working Paper 08/11; 2008 NBER Working Paper No. w14086.
4. **Basu A**, Arondekar BV, Abell, J, Singh M, Manning WG. Costs of diabetes and of related microvascular and macrovascular complications among patients with diabetes in the United States.
5. **Basu A**, Manning WG Estimating life-time or episode cost of illness under censoring. York Health Econometrics and Data Group (HEDG) Working Paper 09/09.

IN PREPARATION

1. **Basu A**, Manca A. "Regression estimators for quality of life and quality-adjusted life-years."
2. **Basu A**, Dukic V "Bayesian hierarchical meta-analysis of treatment effects using pre-post summary data with truncated support: An application with antipsychotic drug trials in schizophrenia."
3. Meltzer D, **Basu A** "Can we better inform medical research spending decisions? An application of value of research techniques to muscular dystrophy."
4. **Basu A** "Flexible models for fractional response variables and outcomes with truncated supports."
5. Meltzer D, Alexander C, **Basu A** "Assessing the empiric cost-effectiveness of new technologies."
6. Meltzer D, **Basu A**, Egleston B, Zhang H "Effects of quality of life on the cost effectiveness analysis of prostate cancer."

PUBLICATIONS (abstracts)

1. Meltzer D, **Basu A**, Egleston B (2001) "Structure and early results of a prostate cancer decision model." *Medical Decision Making* 21(6): 517-548.
2. Jani AB, **Basu A**, Heinmann R, Hellman, S (2001) "A Number-Needed to Treat (NNT) analysis for sentinel node dissection for early-stage breast cancer." *The Cancer Journal* Nov-Dec; 7(6).
3. Arondekar BV, **Basu A**, Akhras K, Walton S (2003) "Hospitalization costs and length of stay in postmyocardial infarction patients with heart failure." *Medical Decision Making* 23(6): 552.
4. **Basu A**, Meltzer D (2003) "Spillover effects of patient's health on family members and its implications to cost-effectiveness analysis." *Medical Decision Making* 23(6): 564.
5. **Basu A**, Meltzer D (2003) "Value of information on preference heterogeneity and individualized care." *Medical Decision Making* 23(6): 553.
6. Arondekar BV, **Basu A**, Walton S, Akhras K (2004) "Hospitalization costs and length of stay in post-myocardial infarction patients with heart failure." *Value in Health*, 7(3): 326.
7. Arondekar BV, **Basu A**, Manning WG, Walton S (2004) "Differences in resource utilization in post-MI patients with and without heart failure." *Value in Health*, 7(3): 322.
8. **Basu A**, Meltzer D (2004) "Families, friends and cost-effectiveness analysis." *Value in Health*, 7(3): 371.
9. **Basu A**, Meltzer D (2004) "Expected Value of Symmetry of Information: a framework for assessing the potential value of individualizing care based on patient preferences." *Value in Health*, 7(3): 307.
10. Huang E, **Basu A**, Manning W (2005) "Trends in the utilization of diabetes-related tests." *Medical Decision Making*, 25(1): E3.
11. **Basu A**, Meltzer HY, Dukic V (2005) "Estimating transitions between symptom severity states for schizophrenic patients." *Medical Decision Making*, 25(1): E33.
12. **Basu A**, Arondekar B, Rathouz P (2005) "Impact of heart failure on 1-year costs after myocardial infarction related hospitalization: an application using a flexible link and variance function model." *Medical Decision Making*, 25(1): E11.
13. Van Voorhees BW, Ellis J, Gollan J, **Basu A** (2006) "Risk Prediction index for new onset major depression in the national longitudinal study of adolescent health." *Journal of General Internal Medicine*, 21(4): 127.
14. Van Voorhees BW, Ellis J, Gollan J, **Basu A** (2006) "Intrapersonal, family, school and community factors protective against new onset depression in the national longitudinal study of adolescent health." *Journal of General Internal Medicine*, 21(4): 77.
15. Yin W, **Basu A**, Zhang JX, Sun SX, Lee KY, Alexander GC (2007) "Changes in prescription use and out-of-pocket costs among Medicare eligible adults, 2005-2006". *Value in Health*, 10(3): A4.

POSTER PRESENTATIONS

1. **Basu A**, Alexander KS, Dollimore D, Pendse A "Interpretation of hindered settling behavior of concentrated aqueous suspensions of never-dried magnesium hydroxide." *Association of the American Pharmaceutical Scientists*, Midwest

- Regional Meeting, Chicago, May 1996 and *Pharmaceutics Graduate Students Research Meeting*, Minneapolis, July 1996.
2. **Basu A**, Alexander KS, Dollimore D "Predicting hindered settling behavior in concentrated suspensions." *Association of the American Pharmaceutical Scientists*, Midwest Regional Meeting, Chicago, May 1997.
 3. Jani AB, **Basu A**, Heimann R, and Hellman S. "A Number-Needed to Treat analysis for sentinel node dissection for Early-Stage Breast Cancer." *American Radium Society Annual Meeting*, Coronado, CA, April 2001.
 4. Akhras K, Arondekar BV, **Basu A**, Walton S "Impact of post-MI heart failure on cost of care and resource utilization." *Heart Failure Society of America*, September 2003.
 5. **Basu A**, Meltzer HY, Dukic V "Estimating transitions between symptom severity states for schizophrenic patients." *Twelfth NIMH Biennial Research Conference on the Economics of Mental Health*, September 2004.
 6. Elbert H, **Basu A**, Manning W "Trends in the Complexity of Medication Regimens and Test Ordering for Patients with Diabetes from 1996 to 2000" *Society of General Internal Medicine Annual Meeting*, May 2005.
 7. Schumann JH, Silverman JB, **Basu A**, Masi C "Per pupil investment in primary and secondary education influences obesity in young adults" *Society of General Internal Medicine Annual Meeting*, April 2006.
 8. Schumann JH, Silverman JB, **Basu A**, Masi C "Per pupil education spending effect on teen pregnancy and death rates" *Society of General Internal Medicine Annual Meeting*, April 2006.
 9. Meltzer D, **Basu A**, Cuffel B, Loebel A, Alvir J. "Remission in schizophrenia: A comparison of the cost-effectiveness of 2 dose regimens of ziprasidone versus haloperidol treatment in a 3-year double-blind extension study". *International Congress on Schizophrenia Research*, March, 2007.
 10. Alexander GC, Zhang JX, **Basu A**. "Characteristics of patients receiving pharmaceutical samples and association between sample use and out-of-pocket prescription costs". *International Society for Pharmacoeconomics and Outcomes Research Annual Meeting*, May 2007.
 11. **Basu A**, Meltzer D, Meltzer HY. "Expected value of research on the comparative cost-effectiveness of antipsychotic drugs" *59th Institute on Psychiatric Services*, October 2007; *Society for Medical Decision Making, Annual Meeting*, October 2007; *American College of Neuropsychopharmacology Annual Meeting*, December 2007.
 12. **Basu A**, Manca A. "Regression estimators for quality of life and quality-adjusted life-years" *Society for Medical Decision Making, Annual Meeting*, October 2008.
 13. **Basu A**, Yin W, Alexander CG. Impact of Medicare Part D on the prescription utilization of elderly dual-eligible patients. *International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting*, May 2009.